Case Study – DASA

Challenge

Personalized medicine

Solution

SOPHiA DDM™ for Radiomics and SOPHiA DDM™ Trial Match

Country

Brazil

DASA leverages on the SOPHiA GENETICS multimodal approach in the fight against cancer

Dasa operates a network of diagnostic medicine, hospitals and a care management company, connecting spaces, technologies, knowledge and multiple specialties. Its diagnostic medicine service, including clinical analysis, diagnostic imaging and genetic medicine, is internationally recognized for quality.

Dasa has more than 40,000 employees, contact with 250,000 doctors and take care of 20 million patients per year. The company also performs more than 260 million exams through 900 ambulatories and inpatient sites across the country.

Challenge

Clinicians from Dasa sought to better understand how to orient patients to personalized medicine, confidently detect disease-causing variants, select the right therapy for each and monitor the efficacy of the treatment. They were in need for a solution to optimize use of oncology data collected throughout the diagnostic journey of a patient.

Solution

In 2016 Dasa partnered with SOPHiA GENETICS to accurately analyze, organize and store the hereditary and hematologic disorder data produced from its genetic unit GeneOne in the context of hereditary and hematologic disorders.

In 2020, Dasa expanded its collaboration with SOPHiA GENETICS and adopted SOPHiA DDM™ for Radiomics and SOPHiA DDM™ Trial Match.

Results

Dasa has accelerated clinical trial recruitment, informed by biomarkers and the genetic variants identified by the SOPHiA DDM™ platform. Dasa’s hospital network, Ímpar, joined the community of SOPHiA DDM™ platform users to engage with peers, share knowledge and collaborate with other experts.

With the help of the SOPHiA DDM™ platform, Dasa performs an exponentially growing number of genomic analyses in various areas of oncology.

In addition, SOPHiA DDM™ for Radiomics allows Dasa radiologists and oncologists to make more data-driven informed decisions and enable individualized follow-up of patients throughout their care journey.

“SOPHiA GENETICS has become our partner of choice for Data-Driven Medicine as we help deliver transformative progress for patients thanks to the multimodal data approach here in Latin America, first by integrating radiomics and now clinical trials. Engaging in [SOPHiA DDM™] Trial Match will help clinicians from Dasa understand better how to follow up, treat and orientate patients towards a more personalized medicine.”

Andreza Almeida Senerchia
Head of Clinical Research at Dasa

Related Case Studies

Case Study: Unlocking access to MSK-ACCESS® for robust liquid biopsy analysis Read More

Genomic Diagnostics, Australia Read More

TomaLab Advanced Biomedical Assays Read More

1 2 3 … 5 Next »

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services